Tilray Brands, Inc. income statement TLRY

Annual Quarterly

In Q1 of fiscal 2027, the quarter ended Aug 31, 2026, Tilray Brands, Inc. reported revenue of $257.1 million, up 22.7% from the same quarter a year earlier. It recorded a net loss of $43.1 million. The operating loss came to $24.1 million, an operating margin of -9.4%. Diluted earnings per share were -$0.32.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Aug 31, 2026	Q1 FY2027 Aug 31, 2026	Q4 FY2026 May 31, 2026	Q3 FY2026 Feb 28, 2026	Q2 FY2026 Nov 30, 2025	Q1 FY2026 Aug 31, 2025	Q4 FY2025 May 31, 2025	Q3 FY2025 Feb 28, 2025	Q2 FY2025 Nov 30, 2024
Revenue	963 +15.9%	257 +22.7%	282 +25.5%	207 +11.3%	218 +3.1%	210 +4.7%	225	186	211
Cost of revenue	683 +15.2%	180 +18.2%	191 +21.9%	152 +13.5%	160 +6.9%	152 +8.3%	157	134	150
Gross profit	280 +17.7%	78 +34.9%	91 +33.8%	55 +5.7%	57 -6.1%	57 -3.7%	68	52	61
Research and development	0 +85.9%	0 +117.1%	0 +429.4%	0 -27.1%	0 +30.0%	0 -61.0%	0	0	0
Selling, general and administrative	270 +22.0%	71 +31.9%	75 +43.9%	61 +14.5%	63 +1.3%	54 -3.3%	52	53	62
Restructuring and impairment	15 -52.5%	2 +181.6%	7 -57.8%	4 -33.4%	1 -86.0%	1 -79.5%	17	6	7
Operating income	-89 +96.0%	-24 -1249.8%	-16 +98.9%	-26 +96.5%	-22 +47.2%	2 +105.7%	-1,444	-760	-42
Pretax income	-126 +94.5%	-38 -4861.9%	-24 +98.3%	-23 +97.1%	-40 +52.0%	-1 +97.7%	-1,393	-792	-83
Income tax	21 +117.0%	2 +175.5%	14 +111.1%	2 +64.1%	4 +74.2%	-2 -357.9%	-125	1	2
Net income	-164 +92.4%	-43 -13297.8%	-50 +96.1%	-27 +96.6%	-45 +47.4%	-0 +99.2%	-1,273	-789	-85
Basic EPS	-1.38 -106.7%	-0.32	-0.42 +96.8%	-0.24 +97.2%	-0.41 +58.6%	0.00 +100.0%	-13.02	-8.69	-0.99
Diluted EPS	-1.38 -106.7%	-0.32	-0.42 +96.8%	-0.24 +97.2%	-0.41 +58.6%	0.00 +100.0%	-13.02	-8.69	-0.99
Weighted average shares, basic	119 +214.8%	133 +25.8%	118 +21.0%	113 +24.0%	110 +27.6%	106 -87.9%	98	91	86
Weighted average shares, diluted	119 +214.8%	133 +25.8%	118 +21.0%	113 +24.0%	110 +27.6%	106 -87.9%	98	91	86
Margins
Gross margin	29.12%	30.14%	32.13%	26.58%	26.43%	27.43%	30.12%	28.00%	29.02%
Operating margin	-9.26%	-9.35%	-5.84%	-12.76%	-10.24%	1.00%	-643.10%	-409.05%	-20.01%
Pretax margin	-13.04%	-14.90%	-8.54%	-11.25%	-18.37%	-0.37%	-620.41%	-426.49%	-39.46%
Profit margin	-17.05%	-16.78%	-17.60%	-12.85%	-20.66%	-0.15%	-566.86%	-424.93%	-40.46%

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Medicinal Chemicals & Botanical Products (SIC 2833)
Listed as: TLRY (Nasdaq)
Fiscal year ends: May 31
Headquarters: New York, NY
SEC filer status: Large accelerated filer
SEC CIK: 1731348
Former names: Tilray, Inc. (until Jan 10, 2022)

Other Medicinal Chemicals & Botanical Products companies

All 43 Medicinal Chemicals & Botanical Products companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.